Therapy-induced neuroendocrine prostate cancer
https://doi.org/10.21886/2308-6424-2026-14-3-110-118
Abstract
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a rare and aggressive form of the disease, driven by the tumor's adaptive response to standard androgen deprivation therapy (ADT). Although its primary detection rate is low, t-NEPC accounts for up to 30% of cases of progressive prostate cancer (PCa), according to large-scale international studies. However, despite a significant increase in publications in recent years, many aspects of t-NEPC diagnosis and treatment remain controversial and require validation through large-scale research. This article presents a clinical case of t-NEPC and reviews current data on the molecular-genetic mechanisms and key signaling pathways underlying neuroendocrine differentiation. The aim of this publication is to expand the evidence base and improve the understanding of the clinical manifestations, diagnostic challenges, and therapeutic strategies for this rare disease.
About the Authors
M. P. Korchagin
Blokhin National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Mikhail P. Korchagin
Moscow
K. A. Firsov
Blokhin National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Konstantin Andreyevich Firsov — Cand.Sc. (Med)
Moscow
A. S. Krylov
Blokhin National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Alexander Sergeyevich Krylov — Cand.Sc. (Med)
Moscow
V. B. Matveev
Blokhin National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Vsevolod B. Matveev — Dr.Sc.(Med), Full Prof., Acad. the RAS
Moscow
References
1. Рretl K. Zur Frage der Endokrinie der menschlichen vorsteherdrüse. Virchows Arch. path Anat. 1944;312:392–404. (In German). DOI: 10.1007/BF02655955
2. Kazzaz BA. Argentaffin and argyrophil cells in the prostate. J Pathol. 1974;112(3):189-193. DOI: 10.1002/path.1711120310
3. Kovchenko G.A., Sivkov A.V., Kaprin A.D. The role of chromogranin A determination in the treatment of patients with castration-resistant prostate cancer. Experimental and Clinical Urology. 2024;17(1):75-85. (In Russian). DOI: 10.29188/2222-8543-2024-17-1-75-85
4. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int. 2003;91(5):438-445. DOI: 10.1046/j.1464-410x.2003.03066.x
5. Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1):S122-132. DOI: 10.1038/modpathol.2017.164
6. Weaver MG, Abdul-Karim FW, Srigley J, Bostwick DG, Ro JY, Ayala AG. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16(1):62-68. DOI: 10.1097/00000478-199201000-00009
7. di Sant’Agnese PA, De Mesy Jensen KL. Endocrine-paracrine cells of the prostate and prostatic urethra: an ultrastructural study. Hum Pathol. 1984;15(11):1034-1041. DOI: 10.1016/s0046-8177(84)80246-4
8. So JS, Gordetsky J, Epstein JI. Variant of prostatic adenocarcinoma with Paneth cell-like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Hum Pathol. 2014;45(12):2388-2393. DOI: 10.1016/j.humpath.2014.08.004
9. Patel GK, Chugh N, Tripathi M. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers (Basel). 2019;11(10):1405. DOI: 10.3390/cancers11101405
10. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6(4):503-519. DOI: 10.1677/erc.0.0060503
11. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol. 2000;31(4):406-414. Erratum in: Hum Pathol. 2000;31(6):778. DOI: 10.1053/hp.2000.7295
12. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018;36(24):2492-2503. DOI: 10.1200/JCO.2017.77.6880
13. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846-2850. DOI: 10.1158/1078-0432.CCR-13-3309
14. Tucci M, Zichi C, Buttigliero C, Vignani F, Scagliotti GV, Di Maio M. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther. 2018;11:7353-7368. DOI: 10.2147/OTT.S153764
15. Vlachostergios PJ, Puca L, Beltran H. Emerging Variants of CastrationResistant Prostate Cancer. Curr Oncol Rep. 2017;19(5):32. DOI: 10.1007/s11912-017-0593-6
16. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271-286. DOI: 10.1038/nrurol.2018.22
17. Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, Huang J. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. Mol Cancer Res. 2015;13(3):584-591. DOI: 10.1158/1541-7786.MCR-14-0277-T
18. McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021;27(13):3610-3619. DOI: 10.1158/1078-0432.CCR-20-4616
19. Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clin Cancer Res. 2018;24(4):927-938. DOI: 10.1158/1078-0432.CCR-17-0989
20. Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:e27861. DOI: 10.7554/eLife.27861
21. Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 2015;67(4):673-679. DOI: 10.1016/j.eururo.2014.10.004
22. Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann M, Li W. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016;7(29):45171-45185. DOI: 10.18632/oncotarget.9359
23. Zhang Y, Zheng D, Zhou T, Song H, Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann M, Gleave M, Han H, Xu F, Liao W, Wang H, Li W. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018;9(1):4080. DOI: 10.1038/s41467-018-06177-2
24. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-874. Erratum in: Nature. 2007;446(7137):824. DOI: 10.1038/nature04431
25. Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol. 2013;10(7):405-413. DOI: 10.1038/nrurol.2013.110
26. Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, HessJ, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Deltalike protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484):eaav0891. DOI: 10.1126/scitranslmed.aav0891
27. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi A, Prudovsky I, Landriscina M, Marchionni N, Tarantini F. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res. 2012;10(2):230-238. DOI: 10.1158/1541-7786.MCR-11-0296
28. Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10(1):278. DOI: 10.1038/s41467-018-08133-6
29. McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018;128(1):341-358. DOI: 10.1172/JCI93566
30. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305. DOI: 10.1038/nm.4045
31. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30(4):563-577. DOI: 10.1016/j.ccell.2016.09.005
32. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016;29(4):536-547. DOI: 10.1016/j.ccell.2016.03.001
33. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-495. DOI: 10.1158/2159-8290.CD-11-0130
34. Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJU Int. 2018;122(4):560-570. DOI: 10.1111/bju.14207
Review
For citations:
Korchagin M.P., Firsov K.A., Krylov A.S., Matveev V.B. Therapy-induced neuroendocrine prostate cancer. Urology Herald. 2026;14(3):110-118. (In Russ.) https://doi.org/10.21886/2308-6424-2026-14-3-110-118
Views:
41
JATS XML
Email this article 